For customers who plan to use the product consistently, the 120-count two-pack option typically delivers the best overall value
DEVOTE landmark safety outcomes trial Tresiba U-100 demonstrated no increased risk of major adverse cardiovascular events (MACE) vs insulin glargine U-100 for adults with type 2 diabetes and ASCVD 2,d The secondary confirmatory endpoint showed Tresiba U-100 also demonstrated statistically significant lower rates of severe hypoglycemic events vs insulin glargine U-100 2,e A flat and stable profile 2-4 Tresiba provides a steady rate of absorption into the bloodstream, giving it a flat and stable profile at steady state
Often 23x/week based on plan
Severe dehydration, uncontrolled blood pressure, or symptomatic hypoglycemia would warrant deferral, but these are uncommon with proper dosing and monitoring
Other studies with quercetin, resveratrol and sulforaphane have been done mainly in animal models, but these studies have shown similar results to the human trial mentioned above